The new SPAC intends to search globally, with a focus on healthcare target companies specializing in rare disease and gene/cell therapy. Arisz is led by Chairman of the Board and Chief Executive Officer Echo Hindle-Yang, and Chief Financial Officer Marc Estigarribia.
Total SPAC deal count for 2021 year-to-date is now 547. This offering is expected to close on Monday, November 22.
Chardan is acting as the sole book-running manager for the offering. Loeb & Loeb LLP is serving as Issuer’s Counsel with Ellenoff Grossman & Schole LLP serving as Underwriter’s Counsel. Friedman LLP serves as auditor. Continental Stock Transfer & Trust Company is acting as trustee.